Balance Sheet Details

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Details

Balance Sheet Details

Inventory

The following table provides details of our inventory balance (in thousands):

	September 30, 2020
Raw materials	$	391
Work in process	531
Finished goods	88
Total	$	1,010

As of September 30, 2020, our inventory balance reflects the cost of post-approval manufacturing activities related to our product. During the three and nine months ended September 30, 2020, most of the cost of product sales had a zero-cost basis. Prior to receiving FDA approval for Fintepla, we recorded all manufacturing product costs as research and development expense. As of September 30, 2020, no write-downs of inventory were deemed necessary.

Accrued and Other Current Liabilities

The following table provides details of accrued and other current liabilities (in thousands):

	September 30, 2020		December 31, 2019
Accrued clinical trial expenses	$	13,088	$	18,666
Accrued compensation	8,668		7,179
Other accrued liabilities	10,117		4,074
Common stock warrant liabilities	9		198
Total accrued and other current liabilities	$	31,882	$	30,117